YES1
YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
Overview
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Neratinib, Dasatinib and CH6953755. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.95, affected pathway 0.91, genetic association 0.37, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
- 1 · What it is
YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.
- 2 · What goes wrong in cancer
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation.
- 3 · How drugs use it
No product in this corpus aims at YES1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:12841 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P07947 (protein name, function text, keywords and locations (REST API)); CIViC gene YES1 (3 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Lung Cancer, Lung Small Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000176105 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.55, chronic myelogenous leukaemia, BCR-ABL1 positive 0.58, myeloproliferative neoplasm 0.58, leukaemia 0.59 (GraphQL API, CC0))
Biology
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signalling pathway and mediates AKT-mediated cell migration. Location: Cell membrane; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytosol; Cell junction (UniProt). Locus 18p11.32 (HGNC).
- Breast cancer: CIViC evidence names this disease
- Lung cancer: CIViC evidence names this disease
- Leukaemia: Open Targets association 0.59 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.58 with myeloproliferative neoplasm (MONDO_0020076)
- Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908)
- Small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; CIViC holds 3 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"YES1" OR ABSTRACT:"YES1" OR TITLE:"YES proto-oncogene 1, Src family tyrosine kinase" OR ABSTRACT:"YES proto-oncogene 1, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Yes" OR ABSTRACT:"Tyrosine-protein kinase Yes" OR TITLE:"Yes" OR ABSTRACT:"Yes" OR TITLE:"c-yes" OR ABSTRACT:"c-yes" OR TITLE:"HsT441" OR ABSTRACT:"HsT441") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about YES1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBLK
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetFGR
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetFYN
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetSRMS
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLA2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLD2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLD3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLD4
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).